The quest for a “cure” for aging — a way to remain youthful, even as we get older — is a project as old as humanity. It’s also a big business; products, therapies and treatments intended to moderate or reverse aging are part of a $2 trillion global wellness market that’s only getting bigger. But there have been some recent breakthroughs in the science of longevity that could be pivotal for the field. These discoveries have to do with cellular rejuvenation, which is the idea that scientists could take a cell that has aged, and make it function like a younger version of itself. On this episode of “The Sunday Daily,” the host Rachel Abrams talks with Susan Dominus, a staff writer at The New York Times Magazine, about this new research, the scientists behind it and who is funding this scientific quest for longer lives. On Today’s Episode: Susan Dominus [https://www.nytimes.com/by/susan-dominus] is a staff writer at The New York Times Magazine. Background Reading: Longevity Science Is Overhyped. But This Research Really Could Change Humanity [https://www.nytimes.com/2026/04/27/magazine/cell-rejuventation-biotech-longevity-research-altos-labs.html]. Subscribe today at nytimes.com/podcasts [http://nytimes.com/podcasts] or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher [https://www.nytimes.com/activate-access/audio?source=podcatcher]. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com [https://pcm.adswizz.com] for information about our collection and use of personal data for advertising.